Cart
sales@molnova.com
Linvencorvir
CAS No. 1808248-05-6
Linvencorvir( —— )
Catalog No. M35768 CAS No. 1808248-05-6
Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 330 | In Stock |
|
| 5MG | 250 | In Stock |
|
| 10MG | 359 | In Stock |
|
| 25MG | 581 | In Stock |
|
| 50MG | 761 | In Stock |
|
| 100MG | 1014 | In Stock |
|
| 200MG | 1376 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinvencorvir
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.
-
DescriptionLinvencorvir is an antiviral agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV | Antibiotic
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1808248-05-6
-
Formula Weight598.69
-
Molecular FormulaC29H35FN6O5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (104.39 mM; Ultrasonic (<60°C)
-
SMILESC(OCC)(=O)C=1[C@@H](NC(=NC1CN2C[C@@]3(N(CC2)C(=O)N(CC(C(O)=O)(C)C)C3)[H])C4=NC=CS4)C5=C(C)C(F)=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021
molnova catalog
related products
-
GLP-26
GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.
-
Entecavir
Entecavir(BMS200475; SQ34676) is a guanosine analogue that inhibits reverse transcription, DNA replication and transcription in the viral replication process; oral antiHBV drug.
-
Inarigivir ammonium
Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.
